These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 7752903

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling.
    Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, Kozka IJ, Kirkham DM, Lister CA, Smith SA.
    Diabetes; 1995 Sep; 44(9):1087-92. PubMed ID: 7657033
    [Abstract] [Full Text] [Related]

  • 4. Actions of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic db/db mice.
    Ishikawa Y, Takagi Y, Takeno H, Watanabe K, Tani T.
    Biol Pharm Bull; 1998 Sep; 21(9):928-33. PubMed ID: 9781841
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
    Shibata T, Matsui K, Nagao K, Shinkai H, Yonemori F, Wakitani K.
    Eur J Pharmacol; 1999 Jan 08; 364(2-3):211-9. PubMed ID: 9932726
    [Abstract] [Full Text] [Related]

  • 6. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent.
    Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, Suzuoki Z.
    Diabetes; 1983 Sep 08; 32(9):804-10. PubMed ID: 6354788
    [Abstract] [Full Text] [Related]

  • 7. BM 17.0744: a structurally new antidiabetic compound with insulin-sensitizing and lipid-lowering activity.
    Pill J, Kühnle HF.
    Metabolism; 1999 Jan 08; 48(1):34-40. PubMed ID: 9920142
    [Abstract] [Full Text] [Related]

  • 8. Actions of the novel oral antidiabetic agent HQL-975 in insulin-resistant non-insulin-dependent diabetes mellitus model animals.
    Ishikawa Y, Saito MN, Ikemoto T, Takeno H, Watanabe K, Tani T.
    Diabetes Res Clin Pract; 1998 Aug 08; 41(2):101-11. PubMed ID: 9789716
    [Abstract] [Full Text] [Related]

  • 9. Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice.
    Stevenson RW, Hutson NJ, Krupp MN, Volkmann RA, Holland GF, Eggler JF, Clark DA, McPherson RK, Hall KL, Danbury BH.
    Diabetes; 1990 Oct 08; 39(10):1218-27. PubMed ID: 2210074
    [Abstract] [Full Text] [Related]

  • 10. Effect of benfluorex on insulin secretion and insulin action in streptozotocin-diabetic rats.
    Portha B, Serradas P, Bailbé D, Blondel O, Picarel F.
    Diabetes Metab Rev; 1993 Nov 08; 9 Suppl 1():57S-63S. PubMed ID: 8299491
    [Abstract] [Full Text] [Related]

  • 11. Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats.
    Chang AY, Wyse BM, Gilchrist BJ, Peterson T, Diani AR.
    Diabetes; 1983 Sep 08; 32(9):830-8. PubMed ID: 6354790
    [Abstract] [Full Text] [Related]

  • 12. Hypoglycemic activity of to-kai-san (Chinese medicines) in normal and KK-Ay mice.
    Miura T, Noda M, Fukunaga T, Furuta K.
    J Nutr Sci Vitaminol (Tokyo); 1997 Feb 08; 43(1):11-7. PubMed ID: 9151237
    [Abstract] [Full Text] [Related]

  • 13. Improvement of glucose homeostasis in obese diabetic db/db mice given Plasmodium yoelii glycosylphosphatidylinositols.
    Elased KM, Gumaa KA, de Souza JB, Playfair JH, Rademacher TW.
    Metabolism; 2004 Aug 08; 53(8):1048-53. PubMed ID: 15281017
    [Abstract] [Full Text] [Related]

  • 14. The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.
    Ochman AR, Lipinski CA, Handler JA, Reaume AG, Saporito MS.
    J Pharmacol Exp Ther; 2012 Jul 08; 342(1):23-32. PubMed ID: 22431203
    [Abstract] [Full Text] [Related]

  • 15. Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -+/? mice.
    Chang AY, Wyse BM, Gilchrist BJ.
    Diabetes; 1983 Sep 08; 32(9):839-45. PubMed ID: 6354791
    [Abstract] [Full Text] [Related]

  • 16. Effect of the new oral antidiabetic agent (-)-BM 13.0913.Na on insulin resistance in lean and obese Zucker rats.
    Apweiler R, Kühnle HF, Ritter G, Schell R, Freund P.
    Metabolism; 1995 May 08; 44(5):577-83. PubMed ID: 7752904
    [Abstract] [Full Text] [Related]

  • 17. Rhizoma Anemarrhenae extract ameliorates hyperglycemia and insulin resistance via activation of AMP-activated protein kinase in diabetic rodents.
    Han J, Yang N, Zhang F, Zhang C, Liang F, Xie W, Chen W.
    J Ethnopharmacol; 2015 Aug 22; 172():368-76. PubMed ID: 26162543
    [Abstract] [Full Text] [Related]

  • 18. Antidiabetic activity of perylenequinonoid-rich extract from Shiraia bambusicola in KK-Ay mice with spontaneous type 2 diabetes mellitus.
    Huang M, Zhao P, Xiong M, Zhou Q, Zheng S, Ma X, Xu C, Yang J, Yang X, Zhang TC.
    J Ethnopharmacol; 2016 Sep 15; 191():71-81. PubMed ID: 27286915
    [Abstract] [Full Text] [Related]

  • 19. KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.
    Konda VR, Desai A, Darland G, Grayson N, Bland JS.
    PLoS One; 2014 Sep 15; 9(1):e87848. PubMed ID: 24498211
    [Abstract] [Full Text] [Related]

  • 20. Biochanin A improves insulin sensitivity and controls hyperglycemia in type 2 diabetes.
    Oza MJ, Kulkarni YA.
    Biomed Pharmacother; 2018 Nov 15; 107():1119-1127. PubMed ID: 30257324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.